Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol's $300 Mil. Settlement Leaves $170 Mil. In Reserve For Wholesaler Litigation

This article was originally published in The Pink Sheet Daily

Executive Summary

The company settles a securities class action related to wholesaler inventory accounting practices and Bristol's investment in ImClone's oncologic Erbitux. The settlement awaits final approval by Manhattan district court.

You may also be interested in...



Bristol Agrees To Continue Improving Financial Controls In Settling Shareholder Lawsuit

As part of proposed settlement of a derivative lawsuit, the company will continue to develop and implement oversight and disclosure policies that resulted from a 2004 settlement with SEC.

Bristol Agrees To Continue Improving Financial Controls In Settling Shareholder Lawsuit

As part of proposed settlement of a derivative lawsuit, the company will continue to develop and implement oversight and disclosure policies that resulted from a 2004 settlement with SEC.

Bristol Agrees To One-Month Inventory Limit Under SEC Settlement

Settlement marks first definition of "normal" inventory levels for pharmaceutical industry. Bristol agrees to $150 mil. civil penalty to resolve investigation into "channel stuffing" during 2000-2001.

Related Content

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel